iRhythm sees FY26 revenue $870M-$880M, consensus $862.68M

5 days ago 2

TipRanks

Tue, January 13, 2026 astatine 6:43 AM CST 1 min read

For afloat twelvemonth 2026, expect gross of astir $870 cardinal to $880 million, oregon astir 17% to 18% year-over-year growth, and expect adjusted EBITDA borderline of astir 11.5% to 12.5%. “2025 has been a transformative twelvemonth for iRhythm (IRTC), with beardown execution against our aspiration to thrust best-in-class prime systems, grounds commercialized volumes, implicit 25% year-over-year gross growth, and achieving escaped currency travel positivity for the archetypal clip successful institution history,” said Quentin Blackford, iRhythm’s President and CEO. “Our broad objective grounds programme – including AVALON and CAMELOT publications – continues to reenforce Zio LTCM’s objective superiority successful enactment of addressable marketplace enlargement crossed further populations and attraction settings. As we participate 2026, we’re well-positioned to accelerate our enactment with aggregate maturation catalysts ahead, including deepening penetration successful superior attraction and colonisation wellness done AI-powered hazard stratification partnerships, momentum wrong mobile cardiac telemetry, enlargement into adjacent markets specified arsenic obstructive slumber apnea, and continued planetary execution. With our proven quality to standard efficiently, we’re assured we tin present sustainable, profitable maturation portion transforming cardiac attraction for millions of patients worldwide.”

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected IRTC:

Disclaimer & DisclosureReport an Issue

iRhythm terms people raised to $211 from $202 astatine Goldman Sachs
Evercore ISI upgrades four, downgrades six successful MedTech and Tools
iRhythm upgraded to Outperform from In Line astatine Evercore ISI
iRhythm terms people lowered to $215 from $230 astatine Truist
iRhythm terms people lowered to $220 from $235 astatine Baird

Read Entire Article